The recent identification of key molecular protagonists involved in osteoclast biology has led to the development of new therapeutic approaches of osteolytic diseases using biological molecules which could compete with bisphosphonate therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1359-6446(04)03265-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
Biomedicines
January 2025
Division of Hematology, University Hospital Centre Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia.
Multiple myeloma (MM) is a hematologic disease characterized by the clonal expansion of malignant plasma cells that accumulate in the bone marrow, leading to osteolytic bone disease, hypercalcemia, anemia, and renal dysfunction. Daratumumab was the first monoclonal anti-CD38 antibody approved for the treatment of MM, initially in relapse/refractory settings and, more recently, for newly diagnosed patients. Increased first-line usage of daratumumab will also substantially change treatment approaches for patients with relapsed/refractory disease.
View Article and Find Full Text PDFCorrection: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma.
J Hematol Oncol
January 2025
Experimentelle Unfallchirurgie (ForMED), Justus-Liebig-Universität Gießen, Aulweg 128, 35392, Gießen, Germany.
Mandibular hybrid odontogenic tumor.
Oral Maxillofac Surg
January 2025
Department of Dentistry, State University of Maringá (UEM), Maringá, Brazil.
Background: Hybrid Odontogenic Tumors (HOT) are defined by the presence of two or more independent odontogenic tumors that originate from and affect the same maxillofacial site.
Methods: The present study is the first case report of a mandibular HOT consisting of Ameloblastoma, Calcifying Epithelial Odontogenic Tumor, and Ameloblastic Fibroma.
Case Report: A 37-year-old otherwise healthy male presented with the chief complaint of swelling in the right mandibular body.
Synchronous primary aneurysmal bone cysts: A rare case report and literature review.
Radiol Case Rep
March 2025
Department of Radiology, John H. Stroger, Jr. Hospital of Cook County, 1969 West Ogden Avenue, Chicago, Illinois 60612, USA.
Aneurysmal bone cysts (ABCs) are rare benign osteolytic tumors which occur most frequently within the first two decades of life and can lead to pathological fractures. They have characteristic imaging and histologic features and have historically been classified into two types: primary ABCs, which are true neoplasms linked to specific oncogenes, and secondary ABCs, which are preceded by other bone lesions. The occurrence of multiple concurrent primary ABCs is exceedingly rare; with only a few cases reported in the published literature.
View Article and Find Full Text PDFInfantile Aggressive Aneurysmal Bone Cyst of the Proximal Femur: A Rare Clinical Presentation.
Cureus
December 2024
Orthopaedics and Traumatology, Faculty of Medicine, Ondokuz Mayıs University, Samsun, TUR.
Aneurysmal bone cysts (ABCs) are aggressive, osteolytic lesions usually seen in childhood and young adulthood. The patient's age, location, and behavior of the lesion in the bone may cause patients to present with different clinical findings. Appropriate treatment of these rare, aggressive bone lesions is essential for recurrence.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!